Latest Headlines

  1. Corewell Health And Quest Diagnostics Complete Laboratory Joint Venture Transaction In Michigan 1/5/2026

    Corewell Health and Quest Diagnostics (NYSE: DGX) today announced the completion of the previously announced transaction to establish a laboratory services joint venture to expand access to innovative, quality and affordable laboratory services in Michigan.

  2. WORK Medical Technology Group LTD Subsidiary Obtains Manufacturing Approval For Its AI-Automated Blood Cell Morphology Analyzer 12/29/2025

    WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that its subsidiary, Hunan Saitumofei Co., Ltd., has received manufacturing approval from the Hunan Provincial Medical Products Administration for its Class II medical device, the Artificial Intelligence (“AI”)-Automated Human Blood Cell Morphology Analyzer.

  3. Co-Diagnostics Receives Grant Of Australian Patent Covering Co-Dx PCR Platform Technologies 12/29/2025

    Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Australian Patent Office has granted Australian Patent No. AU2022270084A1, strengthening Co-Dx's intellectual property portfolio surrounding its novel Co-Dx PCR platform*.

  4. Diasorin Receives FDA 510(K) Clearance And CLIA-Waiver For Its First Assay, The 4- Plex Respiratory Panel, On The LIAISON NES Molecular Diagnostics Platform 12/28/2025

    Diasorin today announced that it has received 510(k) clearance and CLIA-waiver from the U.S. Food and Drug Administration (FDA) for its first assay, the FLU A/B, RSV & COVID-19 Panel, to be used on the LIAISON NES platform.

  5. Next Gen Diagnostics Launches NGD Infection Prevention To Provide Real-Time Transmission Detection 12/23/2025

    Next Gen Diagnostics (NGD) today announced that January 1 the Company will spin off its Infection Prevention division into an independent company, NGD Infection Prevention, focused on the implementation of real-time genomic transmission detection across U.S. hospitals.

  6. Guardant Health Japan Receives Regulatory Approval Of Guardant360® CDx Liquid Biopsy As Companion Diagnostic For Imlunestrant In Metastatic Or Recurrent Breast Cancer Previously Treated With Endocrine Therapy 12/22/2025

    Guardant Health Japan Corp. today announced that the Ministry of Health, Labour and Welfare (MHLW) has approved Guardant360® CDx on 23 October 2025 as a companion diagnostic to identify ESR1 mutations in patients with hormone receptor–positive, HER2-negative breast cancer with disease progression following endocrine therapy, for consideration of treatment with imlunestrant.

  7. KDA Group Announces A Collaboration To Integrate New Clinical Alerts Into The Medherize Platform To Support The Adoption Of Next-Generation Sequencing For Breast Cancer Patients 12/22/2025

    KDA Group Inc. (TSXV: KDA) ("KDA" or the "Corporation"), a leader in innovative technological solutions for healthcare professionals, is pleased to announce a collaboration with AstraZeneca Canada to support the utility of next-generation sequencing ("NGS") diagnostic testing for patients with metastatic breast cancer at Hôpital du Saint-Sacrement (CHU de Québec – Université Laval).

  8. Marine Biological Laboratory Explores Human Memory With AI And Virtual Reality 12/22/2025

    The works of Plato state that when humans have an experience, some level of change occurs in their brain, which is powered by memory — specifically long-term memory.

  9. Valar Labs Announces Strategic Partnership With PathNet Lab To Deliver AI-Driven Bladder Cancer Insights Nationwide 12/22/2025

    Valar Labs, a leader in AI-powered diagnostics for oncology, today announced a strategic partnership with PathNet Lab, one of the nation’s foremost pathology laboratories.

  10. Fulgent Genetics Agrees To Acquire Bako Diagnostics And StrataDx 12/22/2025

    Fulgent Genetics, Inc. (“Fulgent”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it has entered into a definitive agreement to acquire selected assets of Bako Diagnostics (“Bako”), a premier pathology laboratory headquartered in Alpharetta, GA and to acquire StrataDx, a premier dermatopathology laboratory located in Lexington, MA.